An observational study in Chronic Myeloproliferative Disorders, Leukemia and Lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Observational
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
OBJECTIVES:
OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.
This study's planned enrollment of 15,000 is above the median of 150 across 115 observational studies indexed under Myeloproliferative Disorders.
Browse Myeloproliferative Disorders studies →UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 429 studies on the registry; 97 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Hematologic malignancies
DISEASE CHARACTERISTICS:
Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
All samples collected during routine clinical care.
All Samples collected during routine clinical care.
Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies
Time frame: 30 years
Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens
Time frame: 30 years
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myeloproliferative Disorders →
UNC Lineberger Comprehensive Cancer Center →